Dr Khushalani
Bossi P et al. Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous squamous cell carcinomas: The I-TACKLE trial. Eur J Cancer 2025;220:115379. Abstract
Breukers SE et al. Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: A randomized phase 2 trial. Nat Med 2025;31(12):4055-64. Abstract
Carter JB et al. Outcomes of primary cutaneous squamous cell carcinoma with perineural invasion: An 11-year cohort study. JAMA Dermatol 2013;149(1):35-41. Abstract
Gibson FT et al. Association of cutaneous immune-related adverse events with improved overall survival among patients with cutaneous squamous cell carcinoma treated with palliative programmed death receptor-1 inhibition. J Am Acad Dermatol 2025;92(6):1399-402. Abstract
Gross ND et al. Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: Follow-up and survival outcomes of a single-arm, multicentre, phase 2 study. Lancet Oncol 2023;24(11):1196-205. Abstract
Gross ND et al. Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma. N Engl J Med 2022;387(17):1557-68. Abstract
Hughes BGM et al. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): An open-label, nonrandomized, multicenter, phase II trial. Ann Oncol 2021;32(10):1276-85. Abstract
Huis in’t Veld EA et al. Oncological outcome after lymph node dissection for cutaneous squamous cell carcinoma. Ann Surg Oncol 2023;30(8):5017-26. Abstract
Karia PS et al. Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women’s Hospital tumor staging for cutaneous squamous cell carcinoma. J Clin Oncol 2014;32(4):327-34. Abstract
Koyfman SA et al. Phase 3 randomized trial (KEYNOTE-630) of adjuvant pembrolizumab (pembro) versus placebo (pbo) for high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) following surgery and radiation (RT). ASCO 2025;Abstract 6000.
Marin-Acevedo JA et al. Cetuximab for immunotherapy-refractory/ineligible cutaneous squamous cell carcinoma. Cancers (Basel) 2023;15(12):3180. Abstract
Migden MR et al. Trial in progress: A phase 3 randomized study of low-dose intralesional cemiplimab versus primary surgery for patients with early-stage cutaneous squamous cell carcinoma (CLEAR CSCC). ASCO 2025;Abstract TPS9612.
Porceddu SV et al. Prognostic subgroups for disease-free survival with cutaneous squamous cell carcinoma of the head and neck: A secondary analysis of a randomized clinical trial. JAMA Otolaryngol Head Neck Surg 2025;151(10):938-45. Abstract
Porceddu SV et al. Postoperative concurrent chemoradiotherapy versus postoperative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck: The randomized phase III TROG 05.01 trial. J Clin Oncol 2018;36(13):1275-83. Abstract
Ran NA et al. Risk factor number and recurrence, metastasis, and disease-related death in cutaneous squamous cell carcinoma. JAMA Dermatol 2025;161(6):597-604. Abstract
Rischin D et al. Adjuvant cemiplimab or placebo in high-risk cutaneous squamous-cell carcinoma. N Engl J Med 2025;393(8):774-85. Abstract
Rischin D et al. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: Extended follow-up of outcomes and quality of life analysis. J Immunother Cancer 2021;9(8):e002757. Abstract
Ruiz ES et al. Efficacy and safety of cosibelimab in advanced cutaneous squamous cell carcinoma: Results from a pivotal open-label study with a median follow-up of ≥2 years. J Am Acad Dermatol 2026;94(1):48-56. Abstract
Dr Wuthrick
Gross ND et al. Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma. N Engl J Med 2022;387(17):1557-68. Abstract
Ladwa R et al. Response-adapted surgical and radiotherapy de-escalation in resectable cutaneous squamous cell cancer using pembrolizumab: The De-Squamate study. J Clin Oncol 2025;43(26):2888-96. Abstract
Veness MJ et al. Surgery and adjuvant radiotherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: Combined treatment should be considered best practice. Laryngoscope 2005;115(5):870-5. Abstract
Wang JT et al. Predictors of outcome in patients with metastatic cutaneous head and neck squamous cell carcinoma involving cervical lymph nodes: Improved survival with the addition of adjuvant radiotherapy. Head Neck 2012;34(11):1524-8. Abstract
Dr Park
Barker CA et al. Phase II, single-arm trial of induction and concurrent vismodegib with curative-intent radiation therapy for locally advanced, unresectable basal cell carcinoma. J Clin Oncol 2024;42(19):2327-35. Abstract
Bertrand N et al. Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study): Neoadjuvant vismodegib in locally advanced basal cell carcinoma. EClinicalMedicine 2021;35:100844. Abstract
Chang ALS et al. Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study. J Am Acad Dermatol 2019;80(2):564-6. Abstract
Dummer R et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br J Dermatol 2020;182(6):1369-78. Abstract
Jones GM et al. Neoadjuvant-adjuvant pembrolizumab in resectable advanced basal cell carcinoma of the head and neck: An open-label, single-arm, phase 1b trial. AACR 2024;Abstract 7518.
Lewis KD et al. Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors. Ann Oncol 2024;35(2):221-8. Abstract
Sekulic A et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update of the pivotal ERIVANCE BCC study. BMC Cancer 2017;17(1):332. Abstract
Stratigos AJ et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: An open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol 2021;22(6):848-57. Abstract
Warrier G et al. Nivolumab (NIVO) +/- relatlimab (RELA) or ipilimumab (IPI) for patients (pts) w/ treatment-naïve or -refractory advanced basal cell carcinoma (aBCC). ESMO 2025;Abstract 1667P.
Dr Patel
Cañueto J et al. Postoperative radiotherapy provides better local control and long-term outcome in selective cases of cutaneous squamous cell carcinoma with perineural invasion. J Eur Acad Dermatol Venereol 2020;34(5):1080-91. Abstract
Conde-Ferreirós A et al. Definition of prognostic subgroups in the T3 stage of the eighth edition of the American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: Tentative T3 stage subclassification. J Am Acad Dermatol 2021;85(5):1168-77. Abstract
Dong J et al. Risk factors for recurrent and metastatic cutaneous squamous cell carcinoma in immunocompromised patients. J Am Acad Dermatol 2020;83(5):1473-5. Abstract
Dusendang JR et al. Cohort and nested case-control study of cutaneous squamous cell carcinoma in solid organ transplant recipients, by medication. J Am Acad Dermatol 2022;86(3):598-606. Abstract
Kim Y et al. Adjuvant radiotherapy may not significantly change outcomes in high-risk cutaneous squamous cell carcinomas with clear surgical margins: A systematic review and meta-analysis. J Am Acad Dermatol 2022;86(6):1246-57. Abstract
Lopez A et al. Immunosuppressed patients are at increased risk of local recurrence, metastasis, and disease specific death from cutaneous squamous cell carcinoma. Arch Dermatol Res 2023;315(5):1429-33. Abstract
Mahajan S et al. Restaging [18F] fludeoxyglucose positron emission tomography/computed tomography scan in recurrent cutaneous squamous cell carcinoma: Diagnostic performance and prognostic significance. J Am Acad Dermatol 2020;82(4):878-86. Abstract
Morgan FC et al. Brigham and Women’s Hospital tumor classification system for basal cell carcinoma identifies patients with risk of metastasis and death. J Am Acad Dermatol 2021;85(3):582-7. Abstract
Morgan FC et al. Factors predictive of recurrence, metastasis, and death from primary basal cell carcinoma 2 cm or larger in diameter. J Am Acad Dermatol 2020;83(3):832-8. Abstract
Ruiz ES et al. Adjuvant radiation following clear margin resection of high T-stage cutaneous squamous cell carcinoma halves the risk of local and locoregional recurrence: A dual-center retrospective study. J Am Acad Dermatol 2022;87(1):87-94. Abstract
Ruiz ES et al. Performance of the American Joint Committee on Cancer Staging Manual, 8th edition vs the Brigham and Women’s Hospital tumor classification system for cutaneous squamous cell carcinoma. JAMA Dermatol 2019;155(7):819-25. Abstract
Ruiz ES et al. The positive impact of radiologic imaging on high-stage cutaneous squamous cell carcinoma management. J Am Acad Dermatol 2017;76(2):217-25. Abstract
Tschetter AJ et al. Long-term clinical outcomes of patients with invasive cutaneous squamous cell carcinoma treated with Mohs micrographic surgery: A 5-year, multicenter, prospective cohort study. J Am Acad Dermatol 2020;82(1):139-48. Abstract